CA2793313C — Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
Assigned to Ogeda SA · Expires 2018-01-23 · 8y expired
What this patent protects
The present invention relates to selective neurokinin 3 (NK-3) receptor selective antagonists of formula I as well as their pharmaceutically acceptable salts and solvates. (see formula I) The present invention is also directed to pharmaceutical compositions comprising such antago…
USPTO Abstract
The present invention relates to selective neurokinin 3 (NK-3) receptor selective antagonists of formula I as well as their pharmaceutically acceptable salts and solvates. (see formula I) The present invention is also directed to pharmaceutical compositions comprising such antagonists of formula I and their use for treating and/or preventing NK-3 receptors mediated disorders such as CNS and peripheral diseases or disorders.
Drugs covered by this patent
- Veozah (FEZOLINETANT) · Astellas Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.